Nasdaq:US$17.92 (-0.64) | HKEX:HK$28.60 (-0.75) | AIM:£2.79 (-0.11)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors